The POLAR genomic signature can help predict the patients with early breast cancer who may benefit from adjuvant radiotherapy ...

OneCell Diagnostics has secured $16 million in a Series A round as it aims to limit cancer recurrence using AI advancements ...

OneCell Diagnostics has secured $16 million in a Series A round as it aims to limit cancer recurrence using AI advancements ...

"Metastatic breast cancer is where breast cancer moves from the origin in the breast through the blood, and through the lymph ...

The study, which is being conducted under an FDA-approved Investigational Device Exemption application, held by GRAIL, leverages GRAIL's targeted methylation platform to detect ctDNA. With GRAIL's ...

GRAIL (GRAL) announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer, or ...

The combination of radiation, chemotherapy, and immunotherapy can reduce tumor size and lead to significantly better survival ...

PeCan-Seq enables sensitive, non-invasive ctDNA analysis for pediatric cancers, with high accuracy for hematologic ...

A study published inClinical Cancer Research found that in patients with unresectable, locally advanced esophageal cancer, ...

New analysis from the DETECT-A study supports MCED testing as a complement to current guideline-recommended screening in lung ...

GSK announced that belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone improved overall survival in ...